Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo
May 28, 06:41 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s Zepbound while adding the company’s newly approved obesity pill Foundayo, and experts discuss how treatment expectations are evolving in lupus care.